Selected research
Industry Growth & Trends
Global Nuclear Drug for Therapeutic Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Nuclear Drug for Therapeutic market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Nuclear Drug for Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Nuclear Drug for Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Nuclear Drug for Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Nuclear Drug for Therapeutic market include Aurobindo Pharma, China Isotope & Radiation, Curium Pharmaceuticals, Dongcheng, International Isotopes, Jubilant Radiopharma, Lantheus, Mundipharma and Q BioMed, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Nuclear Drug for Therapeutic market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Nuclear Drug for Therapeutic market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Nuclear Drug for Therapeutic market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Nuclear Drug for Therapeutic.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Nuclear Drug for Therapeutic market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Nuclear Drug for Therapeutic Market by Company
Aurobindo Pharma
China Isotope & Radiation
Curium Pharmaceuticals
Dongcheng
International Isotopes
Jubilant Radiopharma
Lantheus
Mundipharma
Q BioMed
Bayer
Novartis
Nuclear Drug for Therapeutic Segment by Type
Iodine-131
Radium-223
Lutetium-177
Other
Nuclear Drug for Therapeutic Segment by Application
Lymphoma
Thyroid
Bone Metastasis
Other
Nuclear Drug for Therapeutic Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Drug for Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nuclear Drug for Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Drug for Therapeutic.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Nuclear Drug for Therapeutic companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Iodine-131
- Radium-223
- Lutetium-177
- Other
Applications
- Lymphoma
- Thyroid
- Bone Metastasis
- Other
Companies covered
- Aurobindo Pharma
- China Isotope & Radiation
- Curium Pharmaceuticals
- Dongcheng
- International Isotopes
- Jubilant Radiopharma
- Lantheus
- Mundipharma
- Q BioMed
- Bayer
- Novartis
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Nuclear Drug for Therapeutic Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Nuclear Drug for Therapeutic Market Size by Region (2021-2032)
- 1.4.1 Global Nuclear Drug for Therapeutic Market Size by Region (2021-2026)
- 1.4.2 Global Nuclear Drug for Therapeutic Market Size by Region (2027-2032)
- 1.5 Key Regions Nuclear Drug for Therapeutic Market Size (2021-2032)
- 1.5.1 North America Nuclear Drug for Therapeutic Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Nuclear Drug for Therapeutic Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Nuclear Drug for Therapeutic Market Size Growth Rate (2021-2032)
- 1.5.4 South America Nuclear Drug for Therapeutic Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Nuclear Drug for Therapeutic Market Size Growth Rate (2021-2032)
2 Nuclear Drug for Therapeutic Market by Type
- 2.1 Type Introduction
- 2.1.1 Iodine-131
- 2.1.2 Radium-223
- 2.1.3 Lutetium-177
- 2.1.4 Other
- 2.2 Global Nuclear Drug for Therapeutic Market Size by Type
- 2.2.1 Global Nuclear Drug for Therapeutic Market Size Overview by Type (2021-2032)
- 2.2.2 Global Nuclear Drug for Therapeutic Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Nuclear Drug for Therapeutic Market Size Forecasted by Type (2027-2032)
- 2.3 Global Nuclear Drug for Therapeutic Market Size by Regions
- 2.3.1 North America Nuclear Drug for Therapeutic Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Nuclear Drug for Therapeutic Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Nuclear Drug for Therapeutic Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Nuclear Drug for Therapeutic Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Nuclear Drug for Therapeutic Market Size Breakdown by Type (2021-2026)
3 Nuclear Drug for Therapeutic Market by Application
- 3.1 Type Introduction
- 3.1.1 Lymphoma
- 3.1.2 Thyroid
- 3.1.3 Bone Metastasis
- 3.1.4 Other
- 3.2 Global Nuclear Drug for Therapeutic Market Size by Application
- 3.2.1 Global Nuclear Drug for Therapeutic Market Size Overview by Application (2021-2032)
- 3.2.2 Global Nuclear Drug for Therapeutic Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Nuclear Drug for Therapeutic Market Size Forecasted by Application (2027-2032)
- 3.3 Global Nuclear Drug for Therapeutic Market Size by Regions
- 3.3.1 North America Nuclear Drug for Therapeutic Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Nuclear Drug for Therapeutic Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Nuclear Drug for Therapeutic Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Nuclear Drug for Therapeutic Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Nuclear Drug for Therapeutic Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Nuclear Drug for Therapeutic Industry Trends
- 4.2 Nuclear Drug for Therapeutic Industry Drivers
- 4.3 Nuclear Drug for Therapeutic Industry Opportunities and Challenges
- 4.4 Nuclear Drug for Therapeutic Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Nuclear Drug for Therapeutic Revenue (2021-2026)
- 5.2 Global Nuclear Drug for Therapeutic Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Nuclear Drug for Therapeutic Key Company Headquarters & Area Served
- 5.4 Global Nuclear Drug for Therapeutic Company, Product Type & Application
- 5.5 Global Nuclear Drug for Therapeutic Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Nuclear Drug for Therapeutic Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Nuclear Drug for Therapeutic Players Market Share by Revenue in 2025
- 5.6.3 2025 Nuclear Drug for Therapeutic Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Aurobindo Pharma
- 6.1.1 Aurobindo Pharma Company Information
- 6.1.2 Aurobindo Pharma Business Overview
- 6.1.3 Aurobindo Pharma Nuclear Drug for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Aurobindo Pharma Nuclear Drug for Therapeutic Product Portfolio
- 6.1.5 Aurobindo Pharma Recent Developments
- 6.2 China Isotope & Radiation
- 6.2.1 China Isotope & Radiation Company Information
- 6.2.2 China Isotope & Radiation Business Overview
- 6.2.3 China Isotope & Radiation Nuclear Drug for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 China Isotope & Radiation Nuclear Drug for Therapeutic Product Portfolio
- 6.2.5 China Isotope & Radiation Recent Developments
- 6.3 Curium Pharmaceuticals
- 6.3.1 Curium Pharmaceuticals Company Information
- 6.3.2 Curium Pharmaceuticals Business Overview
- 6.3.3 Curium Pharmaceuticals Nuclear Drug for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Curium Pharmaceuticals Nuclear Drug for Therapeutic Product Portfolio
- 6.3.5 Curium Pharmaceuticals Recent Developments
- 6.4 Dongcheng
- 6.4.1 Dongcheng Company Information
- 6.4.2 Dongcheng Business Overview
- 6.4.3 Dongcheng Nuclear Drug for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Dongcheng Nuclear Drug for Therapeutic Product Portfolio
- 6.4.5 Dongcheng Recent Developments
- 6.5 International Isotopes
- 6.5.1 International Isotopes Company Information
- 6.5.2 International Isotopes Business Overview
- 6.5.3 International Isotopes Nuclear Drug for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 International Isotopes Nuclear Drug for Therapeutic Product Portfolio
- 6.5.5 International Isotopes Recent Developments
- 6.6 Jubilant Radiopharma
- 6.6.1 Jubilant Radiopharma Company Information
- 6.6.2 Jubilant Radiopharma Business Overview
- 6.6.3 Jubilant Radiopharma Nuclear Drug for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Jubilant Radiopharma Nuclear Drug for Therapeutic Product Portfolio
- 6.6.5 Jubilant Radiopharma Recent Developments
- 6.7 Lantheus
- 6.7.1 Lantheus Company Information
- 6.7.2 Lantheus Business Overview
- 6.7.3 Lantheus Nuclear Drug for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Lantheus Nuclear Drug for Therapeutic Product Portfolio
- 6.7.5 Lantheus Recent Developments
- 6.8 Mundipharma
- 6.8.1 Mundipharma Company Information
- 6.8.2 Mundipharma Business Overview
- 6.8.3 Mundipharma Nuclear Drug for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Mundipharma Nuclear Drug for Therapeutic Product Portfolio
- 6.8.5 Mundipharma Recent Developments
- 6.9 Q BioMed
- 6.9.1 Q BioMed Company Information
- 6.9.2 Q BioMed Business Overview
- 6.9.3 Q BioMed Nuclear Drug for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Q BioMed Nuclear Drug for Therapeutic Product Portfolio
- 6.9.5 Q BioMed Recent Developments
- 6.10 Bayer
- 6.10.1 Bayer Company Information
- 6.10.2 Bayer Business Overview
- 6.10.3 Bayer Nuclear Drug for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Bayer Nuclear Drug for Therapeutic Product Portfolio
- 6.10.5 Bayer Recent Developments
- 6.11 Novartis
- 6.11.1 Novartis Company Information
- 6.11.2 Novartis Business Overview
- 6.11.3 Novartis Nuclear Drug for Therapeutic Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Novartis Nuclear Drug for Therapeutic Product Portfolio
- 6.11.5 Novartis Recent Developments
7 North America
- 7.1 North America Nuclear Drug for Therapeutic Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Nuclear Drug for Therapeutic Market Size by Country (2021-2026)
- 7.3 North America Nuclear Drug for Therapeutic Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Nuclear Drug for Therapeutic Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Nuclear Drug for Therapeutic Market Size by Country (2021-2026)
- 8.3 Europe Nuclear Drug for Therapeutic Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Nuclear Drug for Therapeutic Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Nuclear Drug for Therapeutic Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Nuclear Drug for Therapeutic Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Nuclear Drug for Therapeutic Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Nuclear Drug for Therapeutic Market Size by Country (2021-2026)
- 10.3 South America Nuclear Drug for Therapeutic Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Nuclear Drug for Therapeutic Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Nuclear Drug for Therapeutic Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Nuclear Drug for Therapeutic Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst